Phaseline

Targets › TB4

TB4: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Ophthalmology.

Open in Phaseline: the race on TB4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ReGenTreeRGN-259
Thymosin beta 4 (Tβ4) analogue
TB4Phase 3Neurotrophic Keratopathy–

Conditions

Neurotrophic Keratopathy (1)

Modalities

small molecule (1)

Companies

ReGenTree (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.